Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment

NCT06788626 · Not yet recruiting

Last updated 2026-05-28

This clinical trial is testing whether a medication called a glucagon-like peptide 1 receptor agonist can improve recovery outcomes in adults who have had a stroke caused by a large blood vessel blockage and have undergone emergency endovascular treatment.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, single-blind treatment study

Participants 390 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-02 · est. completion 2028-02

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT06788626 ↗

Description as written by the study sponsor.

The goal of this clinical trial is to learn if semaglutide works to treat acute ischemic stroke (AIS). It will also learn about the safety of semaglutide in AIS. The main question it aims to answer is: Does semaglutide improve the 90-days functional outcome in participants with acute large vessel occlusion who receive the endovascular treatment (EVT)? Researchers will compare semaglutide injection to non-injection to see if semaglutide works to improve the functional outcome in participants with EVT. Participants will: * Receive 0.5mg semaglutide injection before (Day 0) and 1 week (Day 7) after EVT , or EVT alone. * Have additional blood test before and after EVT. * Receive neurological assessment before EVT, Day 1, Day 3, Day 5-7 after EVT or on hospital discharge (whichever earlier), Day 90±14 after EVT. Audio or video of the assessment may be recorded if possible. * Receive brain CT + CT angiogram + CT perfusion and MRI after EVT, where the CT scan may be repetitive.

Treatments tested

Semaglutide 0.5 mg Drug

0.5mg semaglutide injection before and 1 week after endovascular treatment.
Standard medical treatment Other

Standard medical management

Main thing measured	The ordinal shift of modified Rankin Scale
Sponsor	Wei Hu
Conditions studied	Acute Ischemic Stroke, Large Vessel Occlusion, Neuroprotective Drugs, Endovascular Treatment
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06788626 ↗